Fulcrum Book Value per Share vs Net Income Analysis
FULC Stock | USD 7.06 0.09 1.26% |
Fulcrum Therapeutics financial indicator trend analysis is much more than just examining Fulcrum Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulcrum Therapeutics is a good investment. Please check the relationship between Fulcrum Therapeutics Book Value Per Share and its Net Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.
Book Value Per Share vs Net Income
Book Value per Share vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulcrum Therapeutics Book Value per Share account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Fulcrum Therapeutics' Book Value per Share and Net Income is -0.78. Overlapping area represents the amount of variation of Book Value per Share that can explain the historical movement of Net Income in the same time period over historical financial statements of Fulcrum Therapeutics, assuming nothing else is changed. The correlation between historical values of Fulcrum Therapeutics' Book Value per Share and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value per Share of Fulcrum Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Book Value per Share i.e., Fulcrum Therapeutics' Book Value per Share and Net Income go up and down completely randomly.
Correlation Coefficient | -0.78 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Fulcrum Therapeutics financial statement analysis. It represents the amount of money remaining after all of Fulcrum Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 15.60, whereas Selling General Administrative is forecasted to decline to about 25.3 M.
2018 | 2019 | 2023 | 2024 (projected) | Interest Income | 518K | 1.5M | 1.7M | 1.8M | Net Interest Income | 518K | 1.5M | 1.7M | 1.8M |
Fulcrum Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Fulcrum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulcrum Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 110.4M | 129.6M | 235M | 226.7M | 257.7M | 164.9M | |
Other Current Liab | 5.9M | 7.7M | 74K | 9.6M | 8.7M | 5.2M | |
Total Current Liabilities | 12.1M | 26.7M | 19.2M | 16.7M | 13.7M | 15.0M | |
Total Stockholder Equity | 87.2M | 95.2M | 211.5M | 198.9M | 235.2M | 142.3M | |
Other Liab | 11.1M | 7.7M | 4.3M | 197K | 177.3K | 168.4K | |
Net Tangible Assets | 87.2M | 95.2M | 211.5M | 198.9M | 228.8M | 240.2M | |
Property Plant And Equipment Net | 87.9M | 8.4M | 7.4M | 16.0M | 12.4M | 16.6M | |
Net Debt | (96.7M) | (57.0M) | (35.4M) | (21.7M) | (14.7M) | (15.5M) | |
Retained Earnings | (150.8M) | (221.6M) | (302.5M) | (412.3M) | (509.7M) | (484.2M) | |
Accounts Payable | 2.2M | 4.1M | 4.8M | 3.6M | 2.8M | 3.2M | |
Cash | 96.7M | 57.1M | 35.4M | 35.1M | 25.6M | 36.9M | |
Non Current Assets Total | 10.4M | 16.7M | 9.0M | 19.2M | 15.5M | 13.4M | |
Non Currrent Assets Other | (78.7M) | 7.2M | 542K | 2.1M | 2.0M | 2.1M | |
Other Assets | 1.2M | 1.7M | 1.6M | 3.2M | 3.7M | 3.9M | |
Cash And Short Term Investments | 96.7M | 112.9M | 218.2M | 202.9M | 236.2M | 147.7M | |
Net Receivables | 111K | 2.7M | 4.1M | 1.1M | 2.2M | 1.7M | |
Common Stock Total Equity | 23K | 28K | 41K | 52K | 59.8K | 62.8K | |
Common Stock Shares Outstanding | 11.0M | 25.4M | 35.4M | 45.0M | 61.3M | 32.4M | |
Liabilities And Stockholders Equity | 110.4M | 129.6M | 235M | 226.7M | 257.7M | 164.9M | |
Non Current Liabilities Total | 11.1M | 7.7M | 4.3M | 11.0M | 8.8M | 7.7M | |
Capital Surpluse | 237.9M | 316.8M | 514.4M | 612.0M | 703.8M | 739.0M | |
Capital Lease Obligations | 46K | 50K | 17K | 13.4M | 10.8M | 11.4M | |
Inventory | 3.0M | (2.8M) | (473K) | (852K) | (766.8K) | (728.5K) | |
Other Current Assets | 284K | 74K | 4.2M | 4.4M | 3.7M | 2.1M | |
Other Stockholder Equity | 237.9M | 316.8M | 514.4M | 612.0M | 744.9M | 404.7M | |
Total Liab | 23.3M | 34.4M | 23.5M | 27.7M | 22.5M | 22.7M | |
Net Invested Capital | 87.2M | 95.2M | 211.5M | 198.9M | 235.2M | 136.8M | |
Property Plant And Equipment Gross | 9.2M | 8.4M | 7.4M | 6.9M | 25.2M | 26.4M | |
Total Current Assets | 100.1M | 112.9M | 226.0M | 207.5M | 242.2M | 151.5M | |
Accumulated Other Comprehensive Income | (110.4M) | (2K) | (397K) | (797K) | (136K) | (142.8K) | |
Non Current Liabilities Other | 150K | 55K | 3.1M | 197K | 226.6K | 215.2K | |
Net Working Capital | 87.9M | 92.8M | 206.8M | 190.8M | 228.5M | 137.5M | |
Short Term Debt | 50K | 17K | 9.6M | 2.6M | 2.2M | 2.3M | |
Common Stock | 23K | 28K | 41K | 52K | 62K | 35.0K | |
Property Plant Equipment | 9.2M | 8.4M | 7.4M | 6.9M | 7.9M | 8.3M | |
Short Long Term Debt Total | 50K | 17K | 469K | 13.4M | 10.8M | 11.4M | |
Current Deferred Revenue | 4.0M | 14.9M | 4.7M | 934K | 840.6K | 798.6K | |
Capital Stock | 23K | 28K | 41K | 52K | 62K | 40.7K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.